We want our technology to be available to as many people as possible. This is why we have decided to both sell our own products and license our technology to other medical device companies. This enables us to reach out effectively to a large, global market.
Our own product portfolio
We have called our own product portfolio ‘BIP’ Bactiguard Infection Protection. This portfolio contains three products:
- The urinary catheter BIP Foley Catheter
- The centrala venous catheter BIP CVC
- The endotracheal tube BIP ETT
We sell our product portfolio through distributors around the world. We perform clinical studies on our BIP portfolio, enabling us to build up knowledge about the effectiveness and safety of the technology. In addition to this, we are well versed in the approval processes of different countries and jurisdictions.
Approval processes often take several years and require extensive clinical studies. Both the clinical studies and our understanding of the approval processes are important factors when developing our distributor network and negotiating license agreements.
The acquisition of our license partner Vigilenz has broadened our product portfolio to include: surgical sutures, mesh, wound
wash, dressings and orthopaedic trauma implants.
We license our technology to medical device companies throughout the world that apply our technology to their own products and sell them under their own brand.
In our license business we receive initial fees related to the right to use our technology for products within a specific application and geographical area. The license revenues also comprise royalties; this is a variable remuneration when the products reach the market and generate sales revenues.
The licensee gains access to our process expertise, while the coating itself – a concentrate of noble metals – is delivered to them.